Navigation Links
Tumor size and level of visceral pleura invasion can impact survival of NSCLC patients
Date:8/19/2009

AURORA, CoA study published in the August 2009 edition of the Journal of Thoracic Oncology found that non-small cell lung cancer (NSCLC) patients could be more accurately staged at diagnosis by taking into account the level of visceral pleura invasion (VPI). VPI is the extension of a tumor beyond the elastic layer of the visceral pleura.

Researchers from the National Cancer Center East in Kashiwa, Japan conducted a review of data from the Japanese Joint Committee for Lung Cancer Registration. After examining the records of 9,758 patients who underwent surgical resection in 1999, the patients were divided into nine groups based on tumor size and VPI.

The status of disease progression is determined through staging by measuring the presence of a localized tumor (T Status), presence of cancerous cells in the lymph nodes (N status) and metastasized tumors (M status). The TNM classification has several subgroups, or stages, that allow physicians to pinpoint the most accurate level of disease progression and develop a treatment plan. Using the International Association for the Study of Lung Cancer's staging model, Junji Yoshida, MD and his team concluded that a tumor 7cm or less with VPI should be upgraded to the next stage in T status.

"This research is extremely necessary in order to fine tune the lung cancer staging guidelines and be sure patients receive the most accurate staging and treatment," said Dr. Yoshida. "Accurate staging and course of treatment can impact the patient's prognosis tremendously."


'/>"/>

Contact: Bethany Fischer
bfischer@spectrumscience.com
202-955-6222
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
3. Study details regulation of vital tumor suppressor gene p53
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. Study suggests brain tumors need treatment with multiple targeted drugs
7. Bright tumors, dim prospects
8. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
9. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... Community for Addiction Recovery (CCAR) will host a second Multiple Pathways of Recovery ... Punta Gorda, Florida. The conference, born from CCAR’s foundational principle – a belief ...
(Date:7/23/2017)... ... July 23, 2017 , ... ... provider of education and training standards for healthcare treatment providers, offers healthcare ... Certification: the iaedp™ Core Curriculum. , Presented as either online or as ...
(Date:7/23/2017)... ... ... Scientists from the University of Exeter reported this month results ... to a medium-paced run for pre-menopausal women, or a slow jog for post-menopausal women, ... care, I understand the importance exercise can play on improving bone health. Although it ...
(Date:7/23/2017)... ONTARIO, CANADA (PRWEB) , ... July 23, 2017 , ... ... a way to gain that elusive college scholarship or even go on to the ... Medicine’s Annual Meeting in Toronto, Canada today say “not so fast.” , ...
(Date:7/23/2017)... , ... July 23, 2017 , ... “I Am Not ... from the mountains who could barely read and write and a brokenhearted young soldier ... disillusioned. The coming of age novel about the power of simple faith is the ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... , July 13, 2017 RK Logistics Group, ... of Pharmacy certification for its Fremont, CA ... solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont Innovation ... to provide such a powerful resource to the hundreds of ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
Breaking Medicine Technology: